Literature DB >> 25102445

Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.

Prashanthi N Thota1, Hyun-Ju Lee2, John R Goldblum3, Xiuli Liu3, Madhusudhan R Sanaka2, Tushar Gohel2, Mehulkumar Kanadiya2, Rocio Lopez4.   

Abstract

BACKGROUND & AIMS: In patients with Barrett's esophagus (BE), low-grade dysplasia (LGD) is a risk factor for esophageal adenocarcinoma (EAC), progressing at variable rates. Patients at higher risk for progression could benefit from intervention. We assessed rates of progression of LGD and indefinite for dysplasia (IND) and risk factors for progression to high-grade dysplasia (HGD) and EAC.
METHODS: We analyzed data from Cleveland Clinic Barrett's Registry on patients with BE and LGD or IND at least 1 year of follow-up from January 1, 2002 through December 31, 2012. Prevalent cases were those diagnosed at or within 1 year of the first endoscopy, and the rest were incident cases.
RESULTS: Among 299 patients with BE and LGD or IND, there were 32 cases of HGD and 10 cases of EAC during a follow-up period of 1577.4 patient-years. The annual incidence rates were 2.4% (95% confidence interval [CI], 1.7%-3.3%) for HGD, 0.6% (95% CI, 0.3%-1.2%) for EAC, and 2.7% (95% CI, 1.9%-3.6%) for HGD or EAC. The rates were higher in men than in women with BE and LGD or IND. Prevalent cases were 3-fold more likely to progress than incident cases. Multifocality and nodules were associated with higher risk of progression to HGD or EAC. None of the patients with IND at index biopsy developed EAC. For every 5-year increase in age, chance of regression increased by 7% (P = .04). Also, for every 1-cm increase in BE length, probability of regression decreased by 6% (P = .016). LGD at index biopsy was associated with 56% lower chance of regression compared with IND (P < .001).
CONCLUSIONS: On the basis of a database analysis of patients with BE, prevalent LGD, male sex, multifocality, and nodules were associated with higher risk for progression to EAC. Older age at LGD diagnosis, IND at index biopsy, and shorter BE length were associated with regression. These findings help in risk stratification of patients with BE and LGD or IND.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; Esophageal Cancer; Patient Management; Tumor

Mesh:

Year:  2014        PMID: 25102445     DOI: 10.1016/j.cgh.2014.07.049

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  18 in total

1.  Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.

Authors:  Rajesh Krishnamoorthi; Jason T Lewis; Murli Krishna; Nicholas J Crews; Michele L Johnson; Ross A Dierkhising; Brenda F Ginos; Kenneth K Wang; Herbert C Wolfsen; David E Fleischer; Francisco C Ramirez; Navtej S Buttar; David A Katzka; Prasad G Iyer
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

Review 2.  Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis.

Authors:  Bashar J Qumseya; Sachin Wani; Sherif Gendy; Ben Harnke; Jacques J Bergman; Herbert Wolfsen
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

3.  Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.

Authors:  M Ma; S Shroff; M Feldman; M DeMarshall; C Price; A Tierney; G W Falk
Journal:  Dis Esophagus       Date:  2017-03-01       Impact factor: 3.429

Review 4.  Clinical significance and management of Barrett's esophagus with epithelial changes indefinite for dysplasia.

Authors:  Prashanthi N Thota; Gaurav Kistangari; Ashwini K Esnakula; David Hernandez Gonzalo; Xiu-Li Liu
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

5.  Yield of Higher-Grade Neoplasia in Barrett's Esophagus With Low-Grade Dysplasia Is Double in the First Year Following Diagnosis.

Authors:  Joel H Rubenstein; Akbar K Waljee; Ben Dwamena; Jacques Bergman; Michael Vieth; Sachin Wani
Journal:  Clin Gastroenterol Hepatol       Date:  2018-01-04       Impact factor: 11.382

Review 6.  Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Thomas M Runge; Julian A Abrams; Nicholas J Shaheen
Journal:  Gastroenterol Clin North Am       Date:  2015-04-09       Impact factor: 3.806

Review 7.  Today's Mistakes and Tomorrow's Wisdom… In Barrett's Surveillance.

Authors:  Pauline A Zellenrath; Carlijn A M Roumans; Manon C W Spaander
Journal:  Visc Med       Date:  2022-03-01

8.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

9.  A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.

Authors:  Rebecca J Critchley-Thorne; Lucas C Duits; Jeffrey W Prichard; Jon M Davison; Blair A Jobe; Bruce B Campbell; Yi Zhang; Kathleen A Repa; Lia M Reese; Jinhong Li; David L Diehl; Nirag C Jhala; Gregory Ginsberg; Maureen DeMarshall; Tyler Foxwell; Ali H Zaidi; D Lansing Taylor; Anil K Rustgi; Jacques J G H M Bergman; Gary W Falk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-13       Impact factor: 4.254

Review 10.  BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Authors:  Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.